Clinical character of pediatric head and neck rhabdomysarcomas: a 7-year retrospective study.

OBJECTIVE The rhabdomysarcoma (RMS) is most common soft tissue carcinoma in children, mostly found in the head and neck with high degree of malignancy. The current study aimed to summarize clinical data and evaluate treatment outcome of cases in a single hospital. METHODS Forty-one (24 male, 17 female) children with newly diagnosed RMS in Beijing Tong Ren Hospital were enrolled between November, 2004 and May, 2011. The. Students' t and Chi tests were then performed on retrospectively reviewed clinical data, followed by survival analysis based on the Kaplan Meier method using SPSS 17.0 software. RESULTS Of all cases, 32 were treated by common chemotherapy, and 3 cases with stage III RMS received high-dose chemotherapy and auto-peripheral blood stem cell transplantation (APBSCT). Side-effects in the former were: I grade for 62.5% (20/32), II grade for 28.1% (9/32), III grade account for 9.275% (3/32). Side-effects of 3 cases with APBSCT: 2 were I grade, 1 was III grade. The median follow-up time of 41 RMS cases was 41 months. Four cases were lost to follow-up, 7 cases recurred, and 5 cases died of cerebral metastasis, witha total survival rate was 86.5% (32/37). CR rate was 67.6% (25/37), PR was 18.9% (7/37). CONCLUSION Multidiscipline treatment including chemotherapy, radiotherapy, surgery and auto-PBSCT is highly recommended for pediatric patients with head and neck RMS.

[1]  S. Sleijfer,et al.  The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. , 2012, Anticancer research.

[2]  J. Meza,et al.  Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. , 2012, International journal of radiation oncology, biology, physics.

[3]  Y. Al-Tonbary,et al.  Epidemiological Characteristics and Survival Studies of Rhabdomyosarcoma in East Egypt: A Five-Year Multicenter Study , 2012, ISRN oncology.

[4]  H. Tamim,et al.  Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon , 2012, Pediatric hematology and oncology.

[5]  James R. Anderson,et al.  Patterns of chemotherapy‐induced toxicities in younger children and adolescents with rhabdomyosarcoma , 2012, Cancer.

[6]  D. Chandler,et al.  Advances in pediatric rhabdomyosarcoma characterization and disease model development. , 2012, Histology and histopathology.

[7]  J. Turner,et al.  Head and Neck Rhabdomyosarcoma , 2011, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[8]  K. Akashi,et al.  Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review , 2011, Bone Marrow Transplantation.

[9]  P. Adamson,et al.  Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group , 2010, Clinical Cancer Research.

[10]  S. Uemoto,et al.  Successful autologous peripheral blood stem cell transplantation with a double‐conditioning regimen for recurrent hepatoblastoma after liver transplantation , 2009, Pediatric transplantation.

[11]  T. Terano,et al.  Successful autologous peripheral blood stem cell transplantation for a patient with primary adrenal lymphoma with hemophagocytic syndrome. , 2008, Clinical lymphoma & myeloma.

[12]  F. Ferrara,et al.  Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype , 2007, Hematological oncology.

[13]  R. Cohn,et al.  Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma , 2007, Pediatric blood & cancer.

[14]  James R. Anderson,et al.  Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Meza,et al.  Dactinomycin (A) and vincristine (V) with or without cyclophosphamide (C) and radiation therapy (RT) for newly diagnosed patients with low-risk embryonal/botryoid rhabdomyosarcoma (RMS). An IRS-V report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (STS COG). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Bardia,et al.  Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Donaldson,et al.  Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV. , 2005, Journal of pediatric surgery.

[18]  M. Stevens,et al.  Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  O. Nielsen,et al.  [Malignant solid tumors in children]. , 1999, Ugeskrift for laeger.

[20]  F. Barr The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. , 1999, Cancer research.

[21]  S. Burdach,et al.  Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. , 1997, Bone Marrow Transplantation.

[22]  E. Gehan,et al.  The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐II , 1993, Cancer.

[24]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.